Cengiz Özemli
Akademisyen
- Thread Author
- #1
## Multiply Labs Develops Robotic Systems for Therapy Production with Nvidia Technology
Multiply Labs has made significant progress in its goal to scale cell and gene therapy manufacturing processes by utilizing Nvidia's open-source Isaac and GR00T robotic simulation and perception technologies.
This development represents a major shift in the biomanufacturing industry, which has traditionally relied on manual processes. The robotic-first bioproduction systems developed by Multiply Labs aim to provide greater consistency, traceability, and operational efficiency in therapy production. This is intended to make personalized treatment methods more widely accessible.
Multiply Labs' systems feature four robotic arms working in parallel to increase production in existing facilities. This aims to achieve up to a 100-fold increase in patient doses per cleanroom area compared to traditional manual processes.
### Nvidia Robotics and AI Integration
The company's integration with Nvidia's infrastructure covers three main areas:
- Digital bioproduction twins: High-fidelity robotic digital twins are created using Nvidia Isaac Sim. This allows for the simulation of new hardware, testing of automation strategies, and in-loop verification of software.
- Manipulation skill training and generalization: The goal is to learn biomanufacturing-related manipulation behaviors using Nvidia Isaac GR00T open robot foundation models.
- Perception processes: Expert demonstrations are converted into training data using Nvidia FoundationPose and FoundationStereo technologies, enabling the learning of biomanufacturing steps.
### Multiply Labs Robotic System Features
- Four robotic arms working in parallel
- Target of up to a 100-fold increase in patient doses per cleanroom area
- High-fidelity digital twins based on Nvidia Isaac Sim
- Foundation robot learning models with Nvidia Isaac GR00T
- Perception and training data generation with Nvidia FoundationPose and FoundationStereo
Multiply Labs' innovative approach aims to expand access to biotherapy by leveraging the power of automation and artificial intelligence in advanced therapy manufacturing.



















